JNJ-63709178

JNJ-63709178 is a bispecific antibody that targets CD3, which is epxressed on T-cells and CD123, which is overexpressed in various hematologic malignancies. JNJ-63709178 can redirect T-cells, resulting in T-cell mediated killing of CD123 positive acute myeloid leukemia (AML) cells. JNJ-63709178 was created under a collaboration between Genmab and Janssen using Genmab's DuoBody technology. JNJ-63709178 is being investigated in acute myeloid leukemia.

Back to top

Acute myeloid leukemia (AML) begins in the bone marrow and often moves quickly into the blood. It may then spread to other parts of the body including the lymph nodes, liver, spleen and central nervous system.1  The average age of AML patients is 68, with the disease uncommon in people under 45.2 According to the American Cancer Society, there will be 19,520 new cases of AML in the United States in 2018.2 JNJ-63709178 is being investigated in a Phase I clinical study to treat relapsed or refractory acute myeloid leukemia. For more information, visit clinicaltrials.gov.



1 American Cancer Society http://www.cancer.org/cancer/leukemia-acutemyeloidaml/overviewguide/leukemia-aml-overview-what-is-aml
2 American Cancer Society http://www.cancer.org/cancer/leukemia-acutemyeloidaml/detailedguide/leukemia-acute-myeloid-myelogenous-key-statistics


Back to top